Prevalence of cancer in relation to signs of periodontal inflammation.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2022
Historique:
received: 15 03 2022
accepted: 06 10 2022
entrez: 21 10 2022
pubmed: 22 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

We investigated the associations between periodontal inflammation (gingivitis and periodontitis) and all-kind malignancies, specifically breast and prostate cancer, in a cohort followed-up for 30 years. The study hypothesis was based on the oral inflammation vs. systemic health paradigm. A sample of 2,168 subjects from an original cohort of 105,718 individuals from the greater Stockholm area in Sweden that had been followed since 1985 was investigated. Swedish national health registers were used in the study. Chi-square tests and logistic multiple regression analyses were conducted. The results showed that periodontitis was significantly associated with any cancer after adjusting for gender, age, income, and education (p = 0.015). The probability of getting cancer increased on average by 38% if the patient had periodontitis vs. had not; the odds ratio was 1.380 (95% confidence interval l.066-1.786). No significant association was observed between periodontitis and breast cancer (p = 0.608), while the association between periodontitis and prostate cancer tended towards significance (p = 0.082). However, no statistically significant difference was found between the observed and the calculated distribution of any cancer in gingivitis groups (p = 0.079). Thus, the study hypothesis was partly confirmed by showing a statistically significant association between periodontitis and any cancer.

Identifiants

pubmed: 36269741
doi: 10.1371/journal.pone.0276375
pii: PONE-D-22-07699
pmc: PMC9586347
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0276375

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Biomarkers. 2022 May;27(3):258-263
pubmed: 35060836
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Periodontol 2000. 2020 Jun;83(1):213-233
pubmed: 32385885
Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2406-12
pubmed: 19745222
PLoS One. 2018 Apr 17;13(4):e0195683
pubmed: 29664916
Breast Cancer Res Treat. 2011 Jun;127(2):497-502
pubmed: 20960226
Front Oncol. 2020 Nov 23;10:597788
pubmed: 33330090
J Periodontol. 2015 May;86(5):611-22
pubmed: 25688694
J Clin Periodontol. 2002 Mar;29(3):260-8
pubmed: 11940147
Am J Cancer Res. 2021 Oct 15;11(10):4994-5005
pubmed: 34765306
Front Genet. 2012 Nov 28;3:268
pubmed: 23226157
J Exp Clin Cancer Res. 2022 Jan 22;41(1):31
pubmed: 35065652
Rep Pract Oncol Radiother. 2020 May-Jun;25(3):422-427
pubmed: 32372882
BJU Int. 2013 Oct;112(6):735-41
pubmed: 23746332
Lancet. 2020 Oct 17;396(10258):1135-1159
pubmed: 33069324
PLoS One. 2014 Jan 08;9(1):e83744
pubmed: 24421902
J Periodontol. 2021 Dec;92(12):1675-1686
pubmed: 34545953
Cancer Treat Rev. 2022 Mar;104:102339
pubmed: 35074727
J Clin Periodontol. 2020 Apr;47(4):406-428
pubmed: 32011029
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):43-50
pubmed: 26689418
Can J Urol. 2008 Feb;15(1):3866-71
pubmed: 18304396
Microorganisms. 2021 Dec 14;9(12):
pubmed: 34946186
Cancer Causes Control. 2014 Aug;25(8):1045-53
pubmed: 24913780
APMIS. 2020 Feb;128(2):80-91
pubmed: 31990107
Infect Disord Drug Targets. 2022;22(4):e200122200389
pubmed: 35048811
Community Dent Oral Epidemiol. 1994 Apr;22(2):106-11
pubmed: 8205774
Cureus. 2021 Sep 5;13(9):e17742
pubmed: 34659955
Adv Dent Res. 2014 May;26(1):47-55
pubmed: 24736704
Asian Pac J Cancer Prev. 2021 Oct 01;22(10):3109-3114
pubmed: 34710985
Oral Dis. 2011 Nov;17(8):779-84
pubmed: 21819493
Philos Trans R Soc Lond B Biol Sci. 2015 Feb 5;370(1661):20140041
pubmed: 25533098
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
BMC Health Serv Res. 2021 Oct 18;21(1):1116
pubmed: 34663302
J Cancer. 2020 May 25;11(16):4716-4723
pubmed: 32626518
Adv Exp Med Biol. 2007;604:67-86
pubmed: 17695721
Adv Urol. 2016;2016:3140372
pubmed: 27429614

Auteurs

Jukka H Meurman (JH)

Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Håkan Källmén (H)

Center for Psychiatry Research Department of Clinical Neurosciences, Karolinska Institutet, Stockholm, Sweden.

Leif C Andersson (LC)

Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Tulay Yucel-Lindberg (T)

Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.

Birgitta Söder (B)

Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH